New hope to slow genetic kidney disease progression
NCT ID NCT06391450
Summary
This study is testing if a diabetes drug called empagliflozin is safe and can help slow down a genetic kidney disease called ADPKD. It will involve 44 adults with rapidly progressing ADPKD, who will take either empagliflozin or a placebo pill daily for 18 months. The main goal is to see if the drug safely reduces the growth of fluid-filled kidney cysts and the loss of kidney function, both in patients taking the standard drug (tolvaptan) and those who are not.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
Conditions
Explore the condition pages connected to this study.